CHEMICAL AND IMMUNOLOGICAL CHARACTERISTICS OF THYMOSIN

胸腺肽的化学和免疫学特性

基本信息

批准号：
3166619
负责人：
ALLAN L GOLDSTEIN
金额：
$ 37.42万
依托单位：
GEORGE WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1979
资助国家：
美国
起止时间：
1979-01-01 至 1990-06-30
项目状态：
已结题

项目摘要

We will continue our research efforts to chemically and biologically characterize the thymosins, a family of hormonal like peptides isolated from bovine thymus. Two thymosin preparations, thymosin fraction 5(TF5) and thymosin yield1 (Tyield1), are active biological response modifiers (BRM's) and have been shown to reconstitute immune function in patients with primary and secondary immunodeficiency diseases. In Phase II trials, Tyield1 was found effective in restoring helper T-cell function and prolonging survival in patients with non-oat lung cancer following radiotherapy (RT). Tyield1 is the first of the BRM's to enter Phase III trials in non-oat cell lung cancer in conjunction with RT. These trials are currently underway at 25 medical centers under the auspices of the RTOG and MAOP cooperative programs of the NCI. During the course of the current grant period, we have identified a number of other thymic peptides which influence neuroendocrine as well as immune circuits and stimulate the release of peptides, such as ACTH, LHRH, GH, prolactin and Beta-endorphin. We have also demonstrated that TF5 and Tyield1 act to modulate production of lymphokines, such as interleukin-2 (IL-2), and upsilon-interferon in peripheral blood lymphocytes. These studies provide the first evidence of a mechanism whereby thymosin may influence post-thymic lymphocytes. The research has the following objectives: -- Chemical characterization of novel thymosins responsible for the range of biological activities in TF5 and TF5A. -- Further definition of the biological properties of these thymic peptides on modulation of immune and neuroendocrine circuits. --Development of monoclonal antibodies and immunoassays for monitoring physiological changes in these peptides with age and/or disease states. --Development of in vitro and in vivo assays for establishing the mechanism(s) of action and physiological roles of these thymic peptides including receptor studies. It is anticipated that these studies will result in the characterization of several new thymic hormones, lymphokines and/or cytokines, which like Tyield1, may help in the development of new treatments for cancer and other diseases associated with a malfunctioning thymus and/or immunosuppression of the host.

我们将继续我们的研究工作进行化学和生物学上表征胸腺素，一种荷尔蒙类（如肽）的家族来自牛胸腺。两种胸腺素制剂，胸腺素分数5（TF5）胸腺素产量1（tyield1）是活性生物学反应改性剂（BRM的）并已被证明可以重建患者的免疫功能原发性和继发性免疫缺陷疾病。在第二阶段试验中，发现Tyield1有效地恢复了辅助T细胞功能，并且在非肌癌患者中延长生存率放疗（RT）。 Tyield1是BRM的第一个进入第三阶段非AIT细胞肺癌的试验与RT结合。这些试验目前正在RTOG的主持下25个医疗中心和NCI的MAOP合作计划。在电流过程中赠款期，我们已经确定了许多其他胸腺肽影响神经内分泌和免疫电路并刺激肽的释放，例如ACTH，LHRH，GH，催乳素和β-内啡肽。我们还证明了TF5和Tyield1的作用以调节生产淋巴细胞因素，例如白介素-2（IL-2）和Upsilon-Interferon 外周血淋巴细胞。这些研究提供了第一个证据的证据胸腺素可能影响胸膜后淋巴细胞的机制。这研究具有以下目标： - 负责该范围的新型胸腺素的化学表征 TF5和TF5A中的生物活性。 - 这些胸腺肽的生物学特性的进一步定义关于免疫和神经内分泌电路的调节。 - 开发单克隆抗体和用于监测的免疫测定这些肽与年龄和/或疾病状态的生理变化。 - 开发体外和体内测定法这些胸腺肽的作用和生理作用机制包括受体研究。预计这些研究将导致表征几种新的胸腺激素，淋巴因子和/或细胞因子喜欢 tyield1，可能有助于开发癌症和其他癌症的新疗法与胸腺功能故障和/或免疫抑制相关的疾病主持人。

项目成果

期刊论文数量（55）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Current status of thymosin and other hormones of the thymus gland.

胸腺素和胸腺其他激素的现状。

DOI：
10.1016/b978-0-12-571137-1.50012-8
发表时间：
1981
期刊：
Recent progress in hormone research
影响因子：
0
作者：
Goldstein,AL;Low,TL;Thurman,GB;Zatz,MM;Hall,N;Chen,J;Hu,SK;Naylor,PB;McClure,JE
通讯作者：
McClure,JE

In vitro effects of thymosin and lithium on lymphoproliferative responses of normal donors and HIV seropositive male homosexuals with AIDS-related complex.

胸腺素和锂对正常捐献者和患有艾滋病相关综合症的艾滋病毒血清阳性男性同性恋者的淋巴增殖反应的体外影响。

DOI：
10.1016/0090-1229(87)90051-1
发表时间：
1987
期刊：
Clinical immunology and immunopathology
影响因子：
0
作者：
Sztein,MB;Simon,GL;Parenti,DM;Scheib,R;Goldstein,AL;Goodman,R;DiGioia,R;Paxton,H;Skotnicki,AB;Schulof,RS
通讯作者：
Schulof,RS

Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1.

胸腺素 α 1 抗血清中和 HTLV-III/LAV 复制。